BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
Standard
BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. / Sterz, Jan; Jakob, Christian; Kuckelkorn, Ulrike; Heider, Ulrike; Mieth, Maren; Kleeberg, Lorenz; Kaiser, Martin; Kloetzel, Peter-M; Sezer, Orhan; von Metzler, Ivana.
in: EUR J HAEMATOL, Jahrgang 85, Nr. 2, 2, 2010, S. 99-107.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.
AU - Sterz, Jan
AU - Jakob, Christian
AU - Kuckelkorn, Ulrike
AU - Heider, Ulrike
AU - Mieth, Maren
AU - Kleeberg, Lorenz
AU - Kaiser, Martin
AU - Kloetzel, Peter-M
AU - Sezer, Orhan
AU - von Metzler, Ivana
PY - 2010
Y1 - 2010
N2 - The ubiquitin-proteasome system emerged as a new therapeutic target in cancer treatment. The purpose of this study was to elucidate the effects of the novel proteasome inhibitor BSc2118 on t(4;14) positive and negative multiple myeloma (MM) cells and normal peripheral blood mononuclear cells (PBMNC).
AB - The ubiquitin-proteasome system emerged as a new therapeutic target in cancer treatment. The purpose of this study was to elucidate the effects of the novel proteasome inhibitor BSc2118 on t(4;14) positive and negative multiple myeloma (MM) cells and normal peripheral blood mononuclear cells (PBMNC).
KW - Humans
KW - inhibitors
KW - Cells, Cultured
KW - Cell Line, Tumor
KW - Oligopeptides pharmacology
KW - Translocation, Genetic
KW - Dose-Response Relationship, Drug
KW - Antineoplastic Agents
KW - Apoptosis drug effects
KW - Bone Marrow Examination
KW - Butanes pharmacology
KW - Cell Cycle drug effects
KW - Leukocytes, Mononuclear drug effects
KW - Multiple Myeloma drug therapy
KW - Proteasome Endopeptidase Complex antagonists
KW - Humans
KW - inhibitors
KW - Cells, Cultured
KW - Cell Line, Tumor
KW - Oligopeptides pharmacology
KW - Translocation, Genetic
KW - Dose-Response Relationship, Drug
KW - Antineoplastic Agents
KW - Apoptosis drug effects
KW - Bone Marrow Examination
KW - Butanes pharmacology
KW - Cell Cycle drug effects
KW - Leukocytes, Mononuclear drug effects
KW - Multiple Myeloma drug therapy
KW - Proteasome Endopeptidase Complex antagonists
M3 - SCORING: Zeitschriftenaufsatz
VL - 85
SP - 99
EP - 107
JO - EUR J HAEMATOL
JF - EUR J HAEMATOL
SN - 0902-4441
IS - 2
M1 - 2
ER -